US20150335613 C-terminal HSP90 inhibitors to treat pituitary adenomas

Settings

Stemming

Single Family Member

Include NPL

Feedback

Goto Application

Office

United States of America

Application Number 14758888

Application Date 04.01.2014

Publication Number 20150335613

Publication Date 26.11.2015

Grant Number 09877947

Grant Date 30.01.2018

Publication Kind B2

IPC

View less classifications

CPC

View less classifications

Applicants MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.
Max-Planck-Gesellschaft zur Föderung der Wissenschaften e.V.

Inventors Marcelo Paez-Pereda
Guenter Stalla

Agents Knobbe, Martens, Olson & Bear, LLP

Priority Data 13150314 04.01.2013 EP

Title

(EN) C-terminal HSP90 inhibitors to treat pituitary adenomas

Abstract

(EN)

The present invention relates to C-terminal HSP90 inhibitors, like silibinin, novobiocin and derivatives thereof, stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said compounds and its compositions have been identified as useful for the treatment of pituitary adenomas such as corticotroph adenomas, lactotroph adenomas, somatotroph adenomas and thyrotroph adenomas.

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31	Medicinal preparations containing organic active ingredients
33	Heterocyclic compounds
335	having oxygen as the only ring hetero atom, e.g. fungichromin
357	having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel

C	CHEMISTRY; METALLURGY
07	ORGANIC CHEMISTRY
D	HETEROCYCLIC COMPOUNDS
407	Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/183
02	containing two hetero rings
04	directly linked by a ring-member-to-ring- member bond

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
36	Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
18	Magnoliophyta (angiosperms)
185	Magnoliopsida (dicotyledons)
28	Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
45	Medicinal preparations containing active ingredients not provided for in groups A61K31/-A61K41/132
06	Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

A	HUMAN NECESSITIES
61	MEDICAL OR VETERINARY SCIENCE; HYGIENE
K	PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31	Medicinal preparations containing organic active ingredients
56	Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
57	substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
573	substituted in position 21, e.g. cortisone, dexamethasone, prednisone

Processing

National Phase Entries

Authority File

Settings

Feedback

Goto Application

1. US20150335613 - C-terminal HSP90 inhibitors to treat pituitary adenomas